Alzheimer Disease as a Clinical-Biological Construct
Bruno Dubois,Nicolas Villain,Lon Schneider,Nick Fox,Noll Campbell,Douglas Galasko,Miia Kivipelto,Frank Jessen,Bernard Hanseeuw,Mercè Boada,Frederik Barkhof,Agneta Nordberg,Lutz Froelich,Gunhild Waldemar,Kristian Steen Frederiksen,Alessandro Padovani,Vincent Planche,Christopher Rowe,Alexandre Bejanin,Agustin Ibanez,Stefano Cappa,Paulo Caramelli,Ricardo Nitrini,Ricardo Allegri,Andrea Slachevsky,Leonardo Cruz de Souza,Andrea Bozoki,Eric Widera,Kaj Blennow,Craig Ritchie,Marc Agronin,Francisco Lopera,Lisa Delano-Wood,Stéphanie Bombois,Richard Levy,Madhav Thambisetty,Jean Georges,David T. Jones,Helen Lavretsky,Jonathan Schott,Jennifer Gatchel,Sandra Swantek,Paul Newhouse,Howard H. Feldman,Giovanni B. Frisoni
DOI: https://doi.org/10.1001/jamaneurol.2024.3770
IF: 29.907
2024-12-10
JAMA Neurology
Abstract:This Special Communication discusses a recent revision of the Alzheimer's Association (AA) criteria to define Alzheimer disease (AD) as a purely biological entity, which raises concerns that if diagnosis of AD can be reduced to the sole presence of AD core 1 biomarkers, major uncertainty and variability in the clinical prognosis of patients diagnosed with AD may be introduced.
clinical neurology